Cabral's caveat on KPV-class peptides: powerful pathway suppression, "getting close" to drugs
Closing the segment, Cabral says he does not want to demean the peptide field but is "worried about pushing down too much on certain pathways from these peptides that are much more powerful." Asked rhetorically whether they are drugs, he answers "No, but they're getting close." He says he is sticking with natural lifestyle and formula based approaches rather than peptides, and will discuss specific peptides more "when more and more studies come out." This is stated as personal clinical caution with no supporting evidence cited.
Cabral: KPV derives from a melanocyte-based precursor and acts on NF-kB, lowering IL-6
Answering a listener question on how KPV decreases inflammation, Cabral says from memory that KPV "comes from a melanocyte-based precursor" (transcript: "melanocybased"), works on the "NF-kappa B inflammatory pathway" and "decreases interleukin sixes... IL6 and one other inflammatory marker" which he could not name. He prefaces this with "if I'm remembering correctly" and states he does no research before answering these questions. No study, paper, or citation is given for the mechanism.
Safety and Evidence Limitation Warning: All KPV Data Preclinical Only
The speaker explicitly warns that KPV is not yet proven in people, with every supporting study being either a mouse model, cell culture, or a single lab-based human tissue permeation test. No clinical trials in living subjects have been conducted. This is framed as a critical distinction between preclinical promise and human validation.
KPV Potential Clinical Applications: Gut Issues, Skin Flares, Recurrent Skin Infections
The speaker suggests KPV may be worth investigating for individuals dealing with gut issues, stubborn skin flares, or recurrent skin infections, particularly those who have been told their condition is simply how their body is. This recommendation is framed as a conversation to have with one's own provider. No specific dosages or protocols are mentioned.
FDA Advisory Committee Narrow Vote to Allow KPV Compounding
In July 2026, an FDA advisory committee voted 8 to 6 with one abstention to recommend allowing KPV to be compounded for inflammatory and wound healing conditions. This is a recommendation only and does not constitute final FDA approval. The final approval decision still rests with the FDA.
KPV Potential Clinical Applications: Gut Issues, Skin Flares, and Recurrent Skin Infections
The speaker suggests KPV may be worth investigating for individuals dealing with gut issues, stubborn skin flares, or recurrent skin infections, particularly those who have been told their condition is simply how their body is. This recommendation is framed as a conversation to have with one's own provider rather than a standalone treatment claim. No specific dosages or protocols are mentioned in the transcript.
FDA Advisory Committee 8-6 Vote to Allow KPV Compounding for Inflammatory and Wound Healing Conditions
In July 2026, an FDA advisory committee voted 8 to 6 with one abstention to recommend allowing KPV to be compounded for inflammatory and wound healing conditions. The speaker clarifies this is not a final FDA approval, as that decision still rests with the FDA itself. This represents a significant regulatory milestone for KPV's accessibility.
KPV Overall Evidence Limitation: All Data Preclinical
The speaker explicitly states that every study behind KPV's three benefits — gut, skin, and antimicrobial — is derived from mouse models, cell cultures, or one lab-based human tissue permeation test, not from clinical trials in living subjects. This is framed as an important distinction between what is proven in a petri dish versus what is proven in a human being.
None of the Four Protocol Tools Are in Standard Treatment Guidelines
The speaker explicitly acknowledges that all four tools in the protocol — including the peptides and low-dose GLP-1 use — are not included in standard clinical guidelines. This is framed not as a safety concern but as a structural limitation of guideline development timelines. The speaker describes this as a 'gray zone' of promising, low-risk options that have not yet completed the pathway to becoming standard of care.
BPC-157 and KPV Stack — First-Line Gut Healing Protocol
BPC-157 and KPV are described as a paired combination that is run together as the first phase of the clinic's gut healing protocol. The speaker states this combination is sufficient for many patients. They are used before larazotide, which is reserved for partial responders. No specific dosages or administration routes are mentioned.
Larazotide Used as a Step-Up After BPC-157 and KPV Partial Response
The speaker describes a specific clinical protocol ordering: BPC-157 and KPV are used first because they are sufficient for many patients. Larazotide is reserved as the next step for patients who achieve real improvement on BPC-157 and KPV but do not reach full resolution. This sequential approach implies larazotide is a more advanced or targeted tool.
Warning: Peptide Protocols Require Root Cause Identification First
The speaker warns that peptide-based gut protocols will fail if applied before identifying and removing the underlying triggers driving inflammation. Using larazotide or BPC-157/KPV on a gut still exposed to ongoing inflammatory triggers yields only a fraction of potential benefit. The speaker frames the gut-healing phase as something that must be 'earned' by first reducing the inflammatory load.
Safety Warning: Peptide Protocols Are Not in Standard Treatment Guidelines
The speaker explicitly states that none of the four tools in the protocol — including low-dose GLP-1 agonists for inflammation, LDN, BPC-157, KPV, and larazotide — are included in standard clinical treatment guidelines. This means conventional physicians cannot recommend them in standard practice. The speaker frames this as a 'gray zone' of promising, low-risk options that have not yet completed the pathway to becoming standard of care.
Larazotide as Step-Up Agent When BPC-157/KPV Produce Incomplete Response
Larazotide is specifically positioned as a second-tier intervention for patients who achieve partial but incomplete improvement on BPC-157 and KPV. The speaker notes that applying larazotide to a gut still exposed to ongoing triggers will yield only a fraction of its potential benefit, emphasizing that root-cause identification must precede peptide use. No dosages are specified.
Four-Tool Protocol Stack for Leaky Gut: BPC-157, KPV, Larazotide, LDN, and GLP-1
The speaker describes a four-tool protocol combining two gut-targeted agents (BPC-157 and KPV) and two inflammation-targeted agents (low-dose naltrexone and low-dose GLP-1 agonists), with larazotide as a step-up option. BPC-157 and KPV address the gut lining and inflammatory gene signaling; LDN addresses neuroinflammation; GLP-1 agonists address the systemic metabolic inflammatory environment. The speaker emphasizes that none of these tools are in standard treatment guidelines.
BPC-157 and KPV Stacking Protocol as First-Line Gut Intervention
BPC-157 and KPV are described as a paired combination that is used first in the gut-healing protocol because 'for a lot of people that's enough.' When this combination produces real improvement but not complete resolution, larazotide is introduced as the next step up. No specific dosages or administration routes are mentioned.
KPV Modulates Inflammatory Gene Signaling at the Source
KPV is described as working at the level of gene signaling, specifically turning down the genes that drive the inflammatory response rather than blocking inflammation after it has already been triggered. The speaker calls this the 'most interesting mechanism' in the toolkit. KPV is used alongside BPC-157 as a first-line combination in the gut-healing protocol.
All Four Protocol Tools Are Off-Guideline — Gray Zone Clinical Practice
The speaker explicitly acknowledges that all four tools in the protocol — including GLP-1s used at low doses for inflammation — are not in any clinical treatment guideline. This is framed not as a safety concern but as a structural gap in medicine where promising, low-risk options have not yet completed the pathway to becoming standard of care. Conventional physicians are described as unable to recommend these options due to guideline constraints.
Four-Tool Protocol Stack for Leaky Gut and Chronic Inflammation
The speaker outlines a four-tool clinical protocol: (1) BPC-157 and KPV targeting the gut lining and inflammatory gene signaling, (2) larazotide targeting the zonulin/tight junction pathway, (3) low-dose naltrexone (LDN) targeting neuroinflammation, and (4) low-dose GLP-1 medications (including retatrutide) targeting the metabolic/inflammatory terrain. Two tools work at the gut itself; two work on the inflammation driving it.
Larazotide as Step-Up Therapy After BPC-157 + KPV Partial Response
The clinical protocol described positions larazotide as a second-tier intervention, used specifically when BPC-157 and KPV produce real but incomplete improvement. This sequencing is presented as clinically meaningful — larazotide is not a first-line agent but an escalation option. No dosages are provided.
BPC-157 + KPV Stacking Protocol — First-Line Gut Healing Combination
BPC-157 and KPV are described as a standard first-line pairing in the speaker's clinical protocol for gut healing and inflammation reduction. The combination is used before escalating to larazotide. The rationale is that for many patients this combination alone is sufficient, and larazotide is reserved for those who achieve partial but incomplete improvement. No specific dosages or frequencies are mentioned.
KPV — Gene-Level Suppression of Inflammatory Signaling
KPV is described as working at the level of gene signaling, specifically turning down the genes that drive the inflammatory response rather than blocking inflammation after it has already manifested. The speaker characterizes this as the most mechanistically interesting tool in the gut-healing toolkit. It is typically paired with BPC-157 as a first-line combination.
None of the Four Protocol Tools Are in Standard Clinical Guidelines
The speaker explicitly states that all four tools in the protocol — larazotide, BPC-157, KPV, and low-dose GLP-1 for inflammation — are not included in any standard clinical treatment guidelines. This is framed as the reason conventional physicians do not offer them, not because they are ineffective, but because they have not completed the pathway to becoming standard of care. This is presented as a safety-relevant context for patients considering these interventions.
Four-Tool Protocol Stack for Leaky Gut: Larazotide, BPC-157, KPV, Low-Dose GLP-1
The speaker outlines a four-tool clinical protocol for intestinal permeability: two tools targeting the gut directly (BPC-157/KPV and larazotide) and two targeting the inflammatory environment (low-dose naltrexone and low-dose GLP-1 agonist). The GLP-1 component addresses the metabolic terrain and systemic inflammation, while LDN addresses neuroinflammation. None of these four tools are described as being in standard treatment guidelines.
BPC-157 and KPV Stacking Protocol for Gut Barrier Repair
BPC-157 and KPV are described as a paired combination that is typically run together as the first-line peptide intervention for intestinal permeability. They are used before larazotide and are considered sufficient for many patients. The combination addresses both the physical lining repair (BPC-157) and the upstream inflammatory gene signaling (KPV). No specific dosages are provided.
KPV Mechanism: Gene-Level Suppression of Inflammatory Signaling
KPV is described as operating at the level of gene signaling, specifically turning down the genes that initiate the inflammatory response rather than blocking inflammation after it has already been triggered. The speaker characterizes this upstream mechanism as the most interesting in the gut-repair toolkit. No dosage or frequency is specified.
Larazotide Positioned as Step-Up Therapy After BPC-157 and KPV Partial Response
The speaker describes a specific clinical ordering where BPC-157 and KPV are used first for gut barrier repair, and larazotide is reserved as the next step for patients who achieve partial but incomplete improvement. This sequencing is presented as clinically meaningful, with larazotide described as a more advanced or targeted tool. No dosages are specified for any of the three peptides in this context.
Off-Label, Non-Guideline Status of All Four Protocol Tools — Safety and Access Context
The speaker explicitly acknowledges that all four tools in the described protocol — including low-dose GLP-1 agonists for inflammation, LDN, BPC-157, KPV, and larazotide — are not in standard clinical treatment guidelines. They are described as 'promising,' 'low risk,' and not yet having completed the pathway to becoming standard of care. Standard physicians cannot recommend them within their scope, which is why patients do not receive them through conventional medicine.
Four-Tool Protocol Stack: BPC-157, KPV, Larazotide, LDN, and Low-Dose GLP-1
The complete described protocol for intestinal permeability involves four categories of tools used together: (1) BPC-157 and KPV targeting the gut lining and inflammatory gene signaling; (2) Larazotide targeting the zonulin/tight junction pathway; (3) Low-dose naltrexone targeting neuroinflammation; and (4) low-dose GLP-1 agonists targeting the systemic metabolic inflammatory environment. None of these uses are described as being in standard clinical guidelines.
BPC-157 and KPV Combination as First-Line Gut Healing Stack
BPC-157 and KPV are described as a paired combination that is run together as the first-line intervention in the gut-healing protocol. BPC-157 addresses the physical lining and oxidative damage while KPV addresses upstream inflammatory gene signaling. Together they are considered sufficient for many patients before escalating to larazotide.
KPV — Gene-Level Inflammatory Signaling Suppression
KPV is described as working at the level of gene signaling, specifically turning down the genes that initiate the inflammatory response rather than blocking inflammation after it has already manifested. This upstream mechanism — quieting the instruction that starts inflammation — is highlighted as the most mechanistically interesting tool in the described protocol. No specific dosage is mentioned.
Larazotide as Step-Up Therapy After BPC-157 and KPV Partial Response
In the described clinical protocol, BPC-157 and KPV are used first as the foundational gut-healing peptides. Larazotide is reserved as a next-step escalation for patients who achieve meaningful but incomplete improvement on BPC-157 and KPV. This sequencing is presented as clinically important for optimizing outcomes.
Safety Warning: Sourcing Quality Remains Critical — Legal Status Unchanged Despite Advisory Vote
The speaker issues a direct safety and sourcing warning: because no legal change has occurred, the importance of sourcing peptides from reputable, licensed channels remains exactly as critical as before the vote. Vendors advertising peptides as 'newly legal' following the advisory vote are making claims unsupported by the regulatory record. The speaker recommends obtaining peptides via a licensed prescription through a verifiable medical team.
FDA's Own Advisory Panel Signals That Reviewed Peptides Belong in Pharmacy Compounding — Strongest Regulatory Signal to Date
The speaker characterizes the advisory committee's on-record recommendation as the strongest positive regulatory signal the peptide compounding category has ever received. Having the FDA's own panel publicly state that these peptides belong in pharmacy compounding is described as a meaningful directional shift, even though it does not constitute legalization. This is framed as a significant change in regulatory tone rather than regulatory status.
FDA Compounding Advisory Committee Reviewed Seven Peptides and Recommended Six for 503A Bulk Substances List
On July 23rd and 24th, the FDA's compounding advisory committee reviewed seven peptides and recommended six of them for inclusion on the 503A bulk substances list. BPC-157, TB-500 (referred to as 'TV500' in transcript), KPV, and at least one other unnamed peptide ('M') cleared the review. Only one peptide was voted down. This represents a formal advisory recommendation, not a binding regulatory decision.
Sourcing Quality and Legitimacy Remains as Critical as Before the Advisory Vote
The speaker issues a direct safety and sourcing warning: because nothing has legally changed, the importance of sourcing peptides from legitimate, licensed channels is identical to what it was prior to the advisory vote. Any vendor or provider advertising peptides as 'newly legal' following the committee vote is making a claim unsupported by the regulatory record. The speaker recommends obtaining peptides via licensed prescription through a medical team.
FDA Panel's On-Record Statement Represents Strongest Regulatory Signal Ever for Peptide Compounding
The speaker characterizes the advisory committee's recommendation as a significant directional shift in the regulatory environment for peptides. Having the FDA's own panel state on record that these peptides belong in pharmacy compounding is described as the strongest positive regulatory signal the peptide compounding category has ever received. However, the speaker is careful to distinguish this directional signal from any actual change in legal status.
Safety and Sourcing Warning: Legal Status Unchanged Means Source Quality Remains Critical
The speaker issues an explicit safety and sourcing warning: because no legal change has occurred, the importance of sourcing peptides from licensed, reputable providers is exactly the same as before the vote. Any vendor advertising peptides as 'newly legal' is making a claim unsupported by the regulatory record. The speaker recommends obtaining peptides via a licensed prescription through a verifiable medical team.
FDA Advisory Panel's On-Record Statement Represents Strongest Regulatory Signal Ever for Peptide Compounding
Although legally non-binding, the FDA's own advisory panel going on record to state that these peptides belong in pharmacy compounding is described as the strongest positive regulatory signal the peptide compounding category has ever received. This directional shift is considered significant even in the absence of formal rule changes. The speaker frames this as a meaningful change in regulatory tone rather than legal status.
Advisory Committee Recommendation Carries No Immediate Legal Force — Formal Rulemaking Not Expected Until Late 2027
Despite widespread celebration, the advisory committee vote did not legalize or change the regulatory status of any peptide. The committee is advisory only; the FDA retains final decision-making authority. Formal rulemaking — the step that would actually change legal status — has not yet begun and analysts estimate it will not occur until late 2027. Sourcing standards and legal risk remain unchanged from prior to the vote.
FDA Compounding Advisory Committee Reviewed Seven Peptides, Recommended Six for 503A Bulk Substances List
On July 23rd and 24th, the FDA's compounding advisory committee reviewed seven peptides and recommended six of them for inclusion on the 503A bulk substances list. Peptides confirmed as clearing the vote include BPC-157, TB-500 (referred to as 'TV500' in transcript), KPV, and at least one other ('M', likely incomplete transcription). Only one peptide was voted down. This recommendation applies to pharmacy compounding under the 503A framework.
Medical Supervision Recommended for Peptide Dosing Protocols
The speaker recommends working with a medical team to manage peptide dosing rather than self-adjusting, particularly when flares recur. This is framed as part of a broader approach that combines peptide use with investigation of inflammatory triggers. The recommendation implies that dosing decisions should not be made unilaterally by the patient.
KPV and BPC-157 Stacking Protocol for Inflammation Management
The speaker recommends pairing KPV with BPC-157 as a combined 'healing stack' to address inflammatory conditions. BPC-157 is described as providing systemic calming effects while the underlying trigger is being identified and tracked. This combination is presented as a clinical protocol managed alongside a medical team. No specific dosages, frequencies, or routes of administration are provided for either peptide.
Caution Against Increasing KPV Dose When Flares Return
The speaker explicitly warns against the common patient reflex of escalating KPV dosage when a flare recurs during active dosing. This is characterized as the 'wrong read' of the situation. The recommended response is instead to investigate and address the returning trigger rather than increasing peptide dose. No specific dosage thresholds are mentioned.
KPV Efficacy Loss: Trigger Reactivation vs. Peptide Failure
When KPV appears to stop controlling inflammatory flares during ongoing dosing, the speaker argues this is typically not peptide failure but rather reemergence of an underlying trigger. Identified triggers include dietary reintroductions, gut flares, poor sleep, and autoimmune drivers ramping up. The peptide is framed as continuing to function correctly while the inflammatory input has changed.
Trigger Identification as Essential Adjunct to Peptide Therapy
The speaker emphasizes that peptide therapy alone (KPV and/or BPC-157) is insufficient without concurrent identification of inflammatory triggers such as dietary factors, gut dysfunction, sleep disruption, or autoimmune activity. The protocol described involves running peptides alongside active clinical investigation of root causes with a medical team overseeing dosing. This reflects a functional medicine framework where peptides are adjunctive rather than standalone treatments.
KPV Dosing Caution: Increasing Dose Is Not the Correct Response to Perceived Loss of Efficacy
The speaker explicitly warns against reflexively increasing KPV dosage when a flare returns during active dosing. This is framed as a common but incorrect clinical decision. The recommended approach instead is to identify and address the re-emerging trigger rather than escalating the peptide dose. This functions as an implicit safety/protocol warning, though no specific dose thresholds or adverse effects are cited.
KPV + BPC-157 Stacking Protocol for Systemic Inflammation Management
The speaker recommends pairing KPV with BPC-157 as a combined 'healing stack' to address inflammatory conditions. In this protocol, KPV handles acute inflammatory suppression while BPC-157 is used to 'calm things down' on the systemic side. The combination is described as being used concurrently while the clinician investigates the root trigger driving inflammation. No specific dosages, frequencies, or routes of administration are mentioned for either peptide.
KPV Dose Escalation Warning: Increasing Dose Is Not the Correct Response to Returning Flares
The speaker explicitly cautions against increasing KPV dosage when a flare returns during active dosing, framing this as a common but incorrect clinical reflex. The recommended alternative is to identify and address the re-emerged inflammatory trigger rather than escalating the peptide dose. This functions as a practical safety/protocol warning. No specific dose ranges or upper limits are discussed.
KPV Tachyphylaxis Misconception: Apparent Loss of Efficacy Likely Reflects Trigger Recurrence
The speaker argues that when KPV appears to stop controlling inflammatory flares during ongoing dosing, the peptide itself has not lost efficacy. Rather, the most likely explanation is that an underlying trigger has re-emerged — such as a reintroduced food, gut flare, poor sleep, or an autoimmune driver ramping up. The clinical reflex to increase KPV dose in this scenario is characterized as typically the wrong approach. No dosage thresholds or specific patient data are cited.
KPV Mechanism of Action: Anti-Inflammatory Signaling
KPV is described as a signaling peptide that instructs the body's inflammatory machinery to stand down, producing rapid suppression of inflammatory flares. The speaker characterizes it as quieting the 'fire' quickly. However, KPV is explicitly stated to not address the underlying cause of inflammation — it does not remove the trigger that initiated the flare. No dosage or frequency information is provided.
KPV and 'Close Stack' Combination at Risk Due to Topical-Only Restriction
The speaker references a 'close stack' that includes oral KPV, implying KPV is commonly combined with other compounds in a stacking protocol for gut or immune-related purposes. If KPV is restricted to topical use only, this entire stack would be disrupted. No specific dosages or other stack components are named in this excerpt.
Oral KPV for Gut Conditions at Risk of Being Eliminated by Route Restriction
KPV is commonly used orally for gastrointestinal conditions, but if the FDA restricts it to topical administration only, oral KPV would become unavailable through legal compounding channels. The speaker uses this as a concrete example of how route-of-administration restrictions could nullify the practical benefit of the advisory vote.
FDA May Restrict KPV to Topical Route of Administration Only
The FDA — the same body that opposed these peptides — has authority to define the permitted route of administration in the final rule. The speaker reports the FDA actively floated approving KPV for topical use only, which would eliminate oral KPV formulations. This would be devastating for patients using oral KPV for gut-related conditions.
Misattributing KPV-Induced Fluid Loss as Fat Loss Creates False Progress Benchmarks
The speaker raises a practical caution: if users record the initial scale drop from KPV-related fluid loss as fat loss, they establish an unrealistic rate of progress that cannot be sustained. This leads to the perception of a plateau or stall even when the fat-loss protocol is working correctly. While not a clinical safety warning, this is framed as an important expectation-management consideration for anyone using KPV within a weight-loss program. No dosage information is discussed.
KPV Stacking Within a Broader Medical Weight-Loss Protocol
The speaker indicates that KPV is prescribed by their medical team as part of a structured weight-loss protocol that includes other interventions (implied: GLP-1 or similar medications, protein targets, and eating windows). This represents a stacking or combination-use context rather than standalone KPV use. Viewers are directed to contact the practice for specifics on what the full protocol looks like. No dosages, frequencies, or specific co-administered agents are named.
KPV as a Gut Compound That Enables Other Weight-Loss Interventions
The speaker positions KPV not as a primary fat-loss agent but as a supportive compound that reduces gut inflammation, thereby creating a physiological environment in which other weight-loss tools — described as 'the medication, the protein and the window' (likely referring to GLP-1 medications, dietary protein, and time-restricted eating) — can work more effectively. KPV is described as making those interventions work 'in a body that isn't inflamed.' No dosage information is provided.
KPV Reduces Systemic Fluid Retention via Gut Inflammation Reduction
The speaker claims that KPV acts on tight junctions in the gut wall to reduce intestinal inflammation, and that this anti-inflammatory effect leads to systemic fluid loss. Symptoms of gut-lining inflammation described include tight rings, facial puffiness, and unexplained waistband fluctuation. As inflammation is calmed, the body releases retained water, which is what causes the scale to drop. No dosage or administration protocol is specified.
KPV Does Not Directly Cause Fat Loss
According to the speaker, KPV does not burn fat directly and should not be logged or tracked as a fat-loss compound. Any weight reduction observed on the scale when using KPV is attributed to fluid loss rather than adipose tissue reduction. Misattributing this fluid loss as fat loss can create false expectations and lead users to believe they have stalled when progress is actually continuing normally. No dosage or frequency information is provided in this video.
Administration Route: Oral Delivery Preferred Over Injectable for This Stack
The speaker explicitly specifies oral administration for the KPV and BPC-157 combination, distinguishing it from injectable peptide protocols. This is presented as a deliberate clinical choice, though no mechanistic explanation for preferring oral over injectable delivery for gut-targeted therapy is elaborated upon in this excerpt.
Safety Warning: Compounded Peptides Must Come from a Licensed Pharmacy, Not Unregulated Sources
The speaker issues a safety warning against sourcing peptides from Amazon or research chemical websites, stating that the contents of such capsules cannot be verified. The recommended sourcing is exclusively through a licensed compounding pharmacy with a valid prescription, framed as a quality control and patient safety issue.
Dosage Protocol: 500 mcg Each of KPV and Oral BPC-157 in a Single Capsule
The prescribed protocol described involves 500 micrograms of KPV and 500 micrograms of oral BPC-157 combined in a single capsule. The route of administration is oral, not injectable. No dosing frequency (e.g., once daily, twice daily) is specified in the transcript.
KPV Limitation: Does Not Rebuild Underlying Gut Tissue
The speaker notes a key limitation of KPV used in isolation: while it seals the gut barrier and reduces inflammation, it does not rebuild the damaged tissue underlying the gut wall. This is presented as the rationale for combining KPV with oral BPC-157 rather than using KPV as a standalone therapy.
Clinical Supervision Requirement: Peptide Protocol Should Be Managed by a Medical Team
The speaker emphasizes that the KPV and BPC-157 protocol should be prescribed and managed under clinical supervision with an accessible medical team. This is presented as a safety and management consideration, distinguishing their approach from self-directed peptide use. The recommendation is tied to ongoing monitoring and availability for patient questions.
Safety Warning: Compounding Pharmacy Sourcing Required — Avoid Unregulated Online Sources
The speaker issues a safety warning against purchasing KPV or BPC-157 from Amazon or research chemical websites, citing unknown capsule contents as the primary risk. The recommended sourcing is through a licensed compounding pharmacy via a valid prescription. This is framed as a quality-control and patient safety concern rather than a legal one.
Oral vs. Injectable Administration: KPV and BPC-157 Prescribed Orally
The speaker explicitly specifies that the KPV and BPC-157 combination is administered orally rather than by injection. This is highlighted as a distinguishing feature of their protocol, suggesting oral delivery is considered appropriate and sufficient for gut-targeted effects with these peptides.
Dosage Protocol: 500 mcg KPV + 500 mcg Oral BPC-157 in a Single Capsule
The prescribed protocol described involves 500 micrograms of KPV and 500 micrograms of oral BPC-157 combined in a single oral capsule. The route of administration is explicitly oral, not injectable. This dosage is presented as a clinically supervised prescription formulation.
KPV + Oral BPC-157 Stack: Complementary Dual-Action Gut Repair Protocol
The speaker advocates combining KPV and oral BPC-157 in a single pill, arguing that KPV seals the gut barrier while BPC-157 rebuilds the underlying tissue — together addressing both halves of the gut repair problem. This stacking rationale is presented as the reason neither peptide is prescribed alone in their clinical practice. The combination is framed as synergistic rather than redundant.
KPV Limitation: Does Not Rebuild Gut Tissue Underlying the Barrier
The speaker notes that while KPV addresses inflammation and barrier integrity, it does not rebuild the underlying gut tissue. This limitation is presented as the rationale for combining KPV with oral BPC-157 rather than using KPV as a standalone therapy. The claim is based on the practitioner's clinical framing rather than cited studies.
KPV Mechanism: Tight Junction Sealing and Anti-Inflammatory Action in the Gut
KPV is described as acting on tight junctions in the gut lining — the seals between gut wall cells. When these junctions loosen, substances that should remain in the gut cross into systemic circulation, triggering systemic inflammation. KPV is claimed to calm inflammation and tighten these seals, addressing the inflammatory component of leaky gut.
Advisory Committee Vote Is Non-Binding — FDA Final Decision Timeline Exceeds One Year
The speaker clarifies that the upcoming advisory committee vote is only a recommendation and does not constitute a final FDA ruling. Rulemaking following the committee vote is expected to take more than a year. The speaker characterizes the hearing as a directional signal rather than a resolution.
Advisory Committee Vote Is Non-Binding; Rulemaking Timeline Exceeds One Year
The speaker clarifies an important procedural point: the FDA advisory committee only issues a recommendation and the FDA is not obligated to follow it. Furthermore, any formal rulemaking that follows is expected to take more than a year to complete. The upcoming hearing should therefore be interpreted as an early indicator of regulatory direction, not a final determination.
Regulatory Uncertainty and Sourcing Risk if FDA Tightens Restrictions
The speaker warns that if the FDA advisory committee moves toward tighter restrictions, the source from which patients obtain these peptides will shift from a matter of preference to a legal compliance issue. The upcoming committee date is characterized not as a resolution but as a directional signal. Patients are advised to establish a relationship with a prescribing medical team before rules change.
Current Clinical Prescribing of BPC-157, KPV, TB-500, and MOTS-c
The speaker states that their medical team currently prescribes all four of the Day One peptides under review: BPC-157, KPV, TB-500, and MOTS-c. No specific dosages, protocols, or indications are provided in this transcript. This reflects active clinical use within a medical practice context.
September 2023 FDA Restriction Event — Loss of Legal Access to Peptides
In September 2023, the FDA moved multiple peptides to a restricted list, causing users to lose legal access overnight to compounds they had been using for years. This regulatory action is the backdrop for the upcoming advisory committee review. The speaker frames this as a significant disruption to patients and prescribers alike.
FDA Advisory Committee to Reconsider Seven Restricted Peptides
An FDA advisory committee is scheduled to reconsider seven peptides that were moved to the restricted list in September 2023, removing legal access overnight. Day one of the review covers BPC-157, KPV, TB-500, and MOTS-c. The committee vote is only a recommendation — the FDA is not bound by it, and any subsequent rulemaking process is expected to extend beyond one year.
Peptide and GLP-1 Tools Require Foundation Repair First for Full Efficacy
A key mechanistic claim in the video is that peptide-based tools and GLP-1 agents cannot reach their full anti-inflammatory potential if underlying gut permeability and nervous system dysregulation are not addressed first. The sequencing principle described is: repair the foundation (gut, nutrients, dietary triggers, nervous system) first, then introduce advanced metabolic and peptide tools to amplify what is already working. This is presented as the differentiating factor between a comprehensive protocol and simply administering a single peptide.
Multi-Peptide Stack for Autoimmune Root Cause Protocol
Dr. Jones describes a comprehensive stacked protocol combining oral BPC-157 + KPV (gut lining), Thymosin Alpha-1 (immune balancing), and Larazotide (gut barrier) alongside Low Dose Naltrexone as a coordinated multi-tool approach to autoimmune remission. Each tool is assigned a specific mechanistic job within the stack, and the speaker emphasizes that none of these tools works in isolation. The protocol is presented as requiring medical supervision with ongoing lab monitoring.
Multi-Peptide Stack for Autoimmune Root-Cause Protocol
The speaker outlines a comprehensive stacked protocol combining multiple peptides alongside low-dose naltrexone, each assigned a specific mechanistic role: oral BPC-157 + KPV for gut lining, Thymosin Alpha-1 + Thymosin Beta for immune balancing, and Larazotide for barrier repair. The stack is described as sequenced and supervised, with the explicit warning that no single tool works in isolation. The protocol is positioned as complementary to — not replacing — conventional autoimmune medications. No dosages are provided for any component.
Oral BPC-157 and KPV Combination for Gut Lining Repair in Autoimmune Conditions
Dr. Jones describes using oral BPC-157 combined with KPV as a targeted intervention for gut lining integrity in autoimmune patients. The rationale is that intestinal permeability ('leaky gut') is a primary driver of immune dysregulation and systemic inflammation. These two peptides are stacked together specifically to address the gut as a root-cause system. No specific dosages or frequencies are mentioned in the transcript.
KPV + BPC-157 Application in Autoimmune Cases
The stack is noted to extend beyond gut repair into autoimmune case management, suggesting the practitioner applies it in a broader immune-modulating context. No specific autoimmune conditions, patient outcomes, or dosing protocols for autoimmune use are described. This is a brief, unsupported extension of the primary gut-repair claim. Evidence basis is practitioner opinion only.
KPV + BPC-157 Stack Positioned as Alternative to GLP-1 Agonists for Gut Pathology
The speaker explicitly contrasts this peptide stack against GLP-1 receptor agonists, arguing that GLP-1 drugs do not address underlying gut wall damage or barrier dysfunction. The KPV/BPC-157 combination is presented as the appropriate intervention when a compromised gut is the root cause stalling a health protocol. No head-to-head comparative data is cited. This represents a clinical opinion framing.
Gut Repair Stack as Foundation for Insulin Sensitivity
The speaker claims that repairing gut barrier integrity via this peptide stack improves insulin sensitivity downstream. The mechanism proposed is that a sealed gut reduces immune activation and improves nutrient absorption, which collectively enhances insulin signaling. This is framed as the metabolic 'floor' that supports the efficacy of other compounds. No clinical data or studies are cited.
KPV + BPC-157 Stack for Gut Barrier (Leaky Gut) Repair
The combined stack is specifically claimed to repair intestinal barrier integrity rather than merely reducing systemic inflammation markers. A sealed gut barrier is described as foundational to downstream benefits including nutrient absorption, immune regulation, and insulin sensitivity. No mechanistic citations or clinical data are referenced. This is presented as a practitioner-level clinical rationale.
KPV + BPC-157 Combination Stack for Gut Repair
The speaker recommends combining KPV and BPC-157 as a synergistic 'gut stack,' with KPV addressing active inflammation and BPC-157 handling tissue and vascular reconstruction. This stack is positioned as superior to GLP-1 agonists for gut-specific pathology. It is also noted as applicable to autoimmune cases beyond gut repair alone. No dosages, ratios, or sequencing details are provided in this excerpt.
GLP-1 Agents Are Insufficient for Gut-Driven Protocol Stalls
The speaker claims that GLP-1 receptor agonists are not the appropriate tool when a damaged gut is the underlying cause of a stalled health optimization protocol. KPV and BPC-157 are positioned as the correct intervention in this context. No comparative clinical data or studies are referenced. This is a clinical opinion differentiating peptide-based gut repair from GLP-1 pharmacology.
Gut Barrier Repair as a Foundation for Nutrient Absorption, Immune Calm, and Insulin Sensitivity
The speaker argues that sealing the gut barrier via this peptide stack produces downstream benefits including improved nutrient absorption, reduced immune activation, and enhanced insulin sensitivity. Insulin sensitivity improvement is described as foundational to the effectiveness of other compounds in a broader protocol. No dosages are mentioned and no studies are cited. This is presented as a mechanistic rationale from the speaker's clinical framework.
Oral Bioavailability of KPV and BPC-157
The speaker claims both KPV and BPC-157 are orally stable, meaning injection is not required to achieve therapeutic effect. This is presented as a practical advantage for patient compliance and protocol accessibility. No pharmacokinetic data, studies, or oral dosing specifics are cited. The claim is asserted without reference to supporting evidence.
KPV + BPC-157 Stack Repairs Gut Barrier Rather Than Only Reducing Systemic Inflammation
The speaker distinguishes this peptide stack from systemic anti-inflammatory approaches by claiming it repairs the gut barrier directly, rather than merely lowering inflammation markers in the blood. This positions the stack as addressing root structural dysfunction rather than symptomatic relief. No mechanistic citations or study references are provided. The framing is clinical opinion.
KPV + BPC-157 Combination Stack for Gut and Autoimmune Cases
The speaker recommends combining KPV and BPC-157 as a synergistic 'gut stack,' with KPV addressing active inflammation and BPC-157 handling tissue and vascular reconstruction. This stack is specifically highlighted for gut dysfunction and autoimmune cases. No dosages, timing, or sequencing details are provided in this excerpt. The recommendation is framed as a clinical protocol from the speaker's practice.
KPV for Gut Wall Inflammation Reduction
KPV is presented as targeting inflammation specifically residing in the gut wall. The speaker positions it as the anti-inflammatory component of a two-peptide gut repair stack. No dosage, frequency, or route details are provided. The claim is based on the speaker's clinical framing rather than cited studies.
Sequence-Dependent Protocol: Foundation Before Peptide/GLP-1 Intervention
The speaker emphasizes that the order of interventions is critical: foundational metabolic work (low-carb diet under 50g net carbs, therapeutic fasting, inflammation reduction) must precede the introduction of retatrutide or any peptide tools. Skipping this sequence is described as the primary reason retatrutide fails or worsens outcomes in insulin-resistant PCOS patients. This sequencing principle is presented as a core clinical protocol derived from the speaker's practice experience.
BPC-157 + KPV + Larazotide Stack for Gut-Inflammation Axis in PCOS
The speaker describes a stacked combination of BPC-157, KPV, and larazotide used together to address the gut lining and inflammation components of the PCOS metabolic protocol. Each peptide is assigned a distinct role: BPC-157 and KPV for gut lining repair, larazotide for barrier tightening. This stack is used as an adjunct to the primary metabolic intervention (retatrutide) and foundational lifestyle work, not as a standalone treatment.
Safety Warning: Retatrutide and All Protocol Medications Contraindicated in Pregnancy or Pre-Conception
The speaker issues an explicit safety warning that all medications and peptides discussed in the protocol are not recommended during pregnancy and should be stopped well ahead of any attempt to conceive, with timing individualized by a prescriber. This is flagged as non-negotiable and particularly relevant given that many women with PCOS are trying to conceive. The warning applies to the full protocol stack, not just retatrutide.
Peptide and Medication Stack for Inflammation and Gut Repair in PCOS
The speaker describes a stacking combination of BPC, KPV, and larazotide used together alongside metabolic tools (including retatrutide) to address the inflammation and gut lining components of the PCOS protocol. Low-dose naltrexone is also mentioned in this same stack context (though noted as not technically a peptide). The stack is described as targeting two of the five identified failing systems: gut microbiome disruption and chronic inflammation.
KPV Peptide for Gut Lining Repair and Inflammation in PCOS Protocol
KPV is mentioned alongside BPC as a peptide used to help repair gut lining within the broader five-system metabolic protocol for PCOS. It is categorized as a support tool targeting the gut and inflammation systems. No dosage, route of administration, or frequency is specified.
BPC and KPV for Gut Lining Repair in PCOS Metabolic Protocol
BPC (referred to alongside KPV) is described as a targeted peptide layered into the protocol specifically to help repair gut lining as part of addressing the gut-inflammation axis in PCOS/PMOS. The speaker frames these as support players addressing one of five failing systems (gut microbiome and leaky gut) rather than primary therapeutic agents. No dosages or frequencies are mentioned.
Prescribed Peptides with 503A Pharmacy Oversight as a Service Offering
The speaker mentions that their clinic offers prescribed peptides sourced from 503A compounding pharmacies with real medical team oversight, as an alternative pathway for patients not seeking a full functional medicine workup. This is presented as a safety and legitimacy differentiator from self-sourcing peptides via the internet or Reddit. No specific peptides, dosages, or protocols are detailed in this context.
Peptide Stack: BPC-157 + KPV + Larazotide for Gut-Inflammation Axis in PCOS
The speaker describes a specific peptide stacking combination of BPC-157, KPV, and larazotide used together to address the gut lining and inflammation components of the PCOS/insulin resistance protocol. These three agents are layered in alongside the primary metabolic tools (retatrutide) and are described as targeting the gut repair and leaky gut barrier functions within a five-system metabolic map. No dosages or frequencies are provided for any of the three.
KPV for Gut Lining Repair in PCOS Metabolic Protocol
KPV is mentioned alongside BPC-157 as a targeted peptide used to help repair gut lining, addressing the gut/microbiome system that feeds back into inflammation and insulin resistance in PCOS. It is described as a support-layer intervention within a broader five-system functional medicine protocol. No specific dosage or frequency is provided.
BPC-157 and KPV Reduce Gut Inflammation But Do Not Close Tight Junctions
The speaker acknowledges that BPC-157 and KPV are effective at calming gut inflammation, describing this as 'fantastic.' However, he draws a mechanistic distinction: these peptides address downstream inflammation rather than the upstream barrier dysfunction caused by open tight junctions. Larazotide is contrasted as the only peptide that closes the barrier itself. No dosages, frequencies, or study citations are provided for either peptide.
Peptide Protocol Optimization as Distinct Specialty Within Multi-Disciplinary Psoriasis Care
The speaker describes a clinical model where peptide protocol optimization is handled as a distinct specialty alongside functional medicine, with Dr. Jones focusing specifically on peptides and Dr. Allen managing the broader functional medicine protocol. This division of expertise is presented as a differentiator from standard dermatology or standalone peptide clinics. The 'Restore Blueprint' is described as a 12-month protocol integrating baseline labs, personalized nutrition, supplements, and peptide optimization. This context is relevant for understanding how the peptide findings in this video are applied clinically.
Peptides as Amplifiers Within a Foundation-First Framework, Not Standalone Treatments
The speaker explicitly frames peptides as 'amplifiers' that work best only after foundational systems (gut health, inflammation, nutrients, dietary triggers, nervous system) have been addressed. This is described as a 'foundation first' philosophy, meaning peptides are not positioned as replacements for lifestyle and dietary interventions but as tools that enhance outcomes when layered on top of a corrected physiological foundation. This framing is a key safety and efficacy caveat for the entire peptide protocol discussed.
KPV Peptide Mechanism: Targeted Downregulation of Pro-Inflammatory Skin Signals
KPV is described as specifically modulating the inflammation signals responsible for the skin's overreaction in psoriasis, distinct from BPC's gut-focused mechanism. The speaker positions KPV as addressing the downstream skin-level inflammatory signaling rather than the upstream gut permeability issue. This mechanistic differentiation is the stated rationale for combining the two peptides into a single stack. No specific cytokine targets, dosages, or clinical trial references are provided for KPV.
BPC-KPV + Thymosin Alpha-1 Combination Stack for Psoriasis
The speaker references a specific multi-peptide stacking protocol combining BPC-KPV with Thymosin Alpha-1 as part of their clinic's psoriasis treatment approach. This stack is described as being optimized alongside LDN (low-dose naltrexone) within a broader 'Restore Blueprint' protocol overseen by both a functional medicine doctor and a peptide specialist. The speaker teases a dedicated video covering exact dosing, stacking rationale, and observed timelines. No specific dosages are disclosed in this video.
BPC-KPV Oral Stack for Leaky Gut and Skin Inflammation in Psoriasis
Dr. Jones describes a combined oral peptide stack of BPC and KPV used in their clinical practice for psoriasis patients. BPC is cited for its potential to seal leaky gut — the primary fuel source for systemic immune activation — while KPV is described as targeting specific inflammation signals driving skin overreaction. The combination is presented as addressing two distinct pathological drivers (gut permeability and skin-directed inflammation) simultaneously with a single stack. No specific dosages or frequencies are mentioned.
Peptide Censorship and Research Study Labeling Explained
The speaker explains that peptide-related content is labeled as 'research studies' or 'research playbooks' because discussing peptide protocols directly results in censorship, throttling, or content removal on social media platforms. He contrasts this with the ability to freely discuss pharmaceutical drugs and their off-label uses. This is presented as context for why peptide information is framed in research terminology.
KPV Mechanism: Suppression of TNF-alpha, IL-6, and IL-1 Beta Inflammatory Cytokines
The speaker describes chronic systemic inflammation as driven by sustained TNF-alpha, IL-6, and IL-1 beta signaling, which attack endothelial tight junction proteins and drive the full cascade of cardiovascular disease, neurodegeneration, and metabolic dysfunction. KPV is implicitly positioned as the molecule that interrupts this cytokine-driven inflammatory loop, though a direct citation linking KPV to cytokine suppression is not explicitly stated in the available transcript.
Overseas Peptides Claimed Safe Contrary to Regulatory Warnings
The speaker directly disputes claims that people are being harmed by overseas peptides, framing regulatory safety warnings as a pharmaceutical industry tactic to suppress competition. He argues that if a therapy cannot be controlled or monetized, it will be made illegal or discredited through fear campaigns. No specific safety data is cited to support this claim.
KPV Presented as Superior Alternative to Statins for Inflammation Resolution
The speaker argues that statins fail to resolve the root cause of cardiovascular disease (inflammation) while causing mitochondrial damage, cognitive decline, diabetes, liver damage, and cancer risk. He positions KPV as the appropriate intervention because it directly addresses the inflammatory pathology rather than suppressing a downstream marker like LDL cholesterol. This is presented as a clinical philosophy rather than a head-to-head trial.
KPV as the Primary Tool for Resolving Chronic Systemic Inflammation
The speaker positions KPV as the central therapeutic molecule for addressing chronic systemic inflammation, which he argues is the root cause of cardiovascular disease, neurodegeneration, cancer, and metabolic dysfunction. He contrasts KPV with statins, arguing that statins suppress some inflammatory markers while creating new pathologies, whereas KPV resolves the underlying inflammatory pathology. No specific dosage protocol is mentioned in the available transcript.
Pre-Blended vs. Individual Peptides: Convenience-Efficacy Trade-Off Assessment
The speaker concludes that pre-blended peptide products represent a modest but real trade-off: approximately 5–10% efficacy loss in exchange for the convenience of fewer injections. This loss is characterized as not a 'deal breaker' under normal usage conditions (vial finished within 20–30 days), contrary to more alarmist claims circulating on social media. The framing implies that for most practical users, the convenience benefit outweighs the marginal efficacy reduction.
Storage Conditions Required to Minimize Peptide Degradation in Solution
The speaker specifies three key storage and reconstitution conditions that apply to approximately 95% of peptides in common circulation and that underpin the stability analysis: time in solution should not exceed 30 days, reconstituted peptides must be stored refrigerated with no direct UV light exposure, and BAC (bacteriostatic) water should be used for reconstitution. Deviating from these conditions would introduce additional degradation variables not accounted for in the efficacy estimates.
Time-Dependent Degradation: Blended Peptide Stability Window of 10–30 Days
The speaker asserts that degradation in pre-blended peptide vials is minimal within a 10–30 day usage window, making the copper-methionine interaction largely negligible at standard dosing. The primary concern arises when a vial is stretched to 45–60 days, at which point cumulative degradation becomes more clinically meaningful. Most users finishing a vial of 'Glow' in approximately 20 days are considered to be well within the safe stability window.
Overall Efficacy Loss Estimate for Pre-Blended Peptide Formulations (e.g., 'Glow')
When accounting for both methionine oxidation and ionic aggregation across all four peptides in the 'Glow' blend, the speaker estimates a total average efficacy loss of approximately 5–10% over 30 days. TB-500 is projected to lose 10–15%, while BPC-157, GHK-Cu, and KPV are each estimated to lose only 2–3%. This trade-off is characterized as minor relative to the convenience benefit of a pre-blended formulation.
Ionic Incompatibility and Aggregation Risk in Mixed-Charge Peptide Blends
Every peptide carries an ionic charge — some are acidic and some are basic. When peptides with opposite charges are mixed in the same vial, they can attract one another and aggregate over time, potentially reducing bioavailability and efficacy. In the 'Glow' blend specifically, BPC-157 and TB-500 are identified as acidic peptides, while GHK-Cu and KPV are identified as basic peptides, creating a theoretical aggregation risk.
BPC-157, KPV, and Low-Dose Naltrexone Stack for Gut Repair in Fatty Liver Protocol
Within the broader clinical protocol described for fatty liver disease, the speaker mentions a combination of low-dose naltrexone, BPC-157, and KPV as tools used for gut repair. This stack is presented as part of addressing intestinal permeability and gut-driven inflammation, which is identified as one of five root-cause systems contributing to fatty liver disease. No specific dosages are provided for any of these agents.
Peptides Used Under Medical Supervision as Part of Root Cause Functional Medicine
The speaker notes that peptides and LDN are used under medical supervision within their functional medicine program, implying these are not over-the-counter or self-administered protocols. This is the only safety-adjacent statement made regarding peptide use in the video — no contraindications, side effects, or drug interactions are discussed. The speaker positions medical oversight as a key differentiator of their clinic's approach versus self-directed protocols.
Peptides Referenced as Advanced Clinical Tools Most Specialists Are Unaware Of
The speaker frames peptides (alongside LDN) as advanced tools that 'most specialists have never heard of,' positioning them as a distinguishing feature of functional medicine practice versus conventional care. The cost of LDN ($30–$90/month from compounding pharmacies) is mentioned as context for accessibility, though no peptide pricing is given. This framing serves as both a clinical observation and a marketing claim. No safety warnings or contraindications are discussed for the peptides.
Peptides Positioned as Complementary to LDN — Each Addressing Distinct Mechanisms
The speaker explicitly distinguishes the mechanisms of peptides from those of LDN, stating that 'no peptides can do what LDN does' in targeting central nervous system inflammation via microglial pathways. This implies the peptides in the stack are viewed as complementary rather than interchangeable with LDN, each filling a different mechanistic role (gut lining, NF-κB, tight junctions vs. CNS immune modulation). No dosages are specified. This framing positions the combined protocol as superior to any single agent.
Peptide Stack Combined with LDN and GLP-1 as a Multi-Modal Anti-Inflammatory Protocol
The speaker describes layering the peptide stack (BPC-157, KPV, Larazotide) on top of Low Dose Naltrexone (LDN) and micro-dosed GLP-1 medications as a potent combined anti-inflammatory protocol. The GLP-1 micro-dosing is explicitly noted as being used for anti-inflammatory purposes rather than weight loss or diabetes management. No specific peptide dosages are given, though GLP-1 escalation from 2.5 to 10 mg over 6 months is mentioned in a patient case. This is presented as the clinic's advanced multi-system approach.
Peptides Described as Turning Off Inflammation at a Genetic Level
The speaker makes a broad claim early in the video that peptides can 'turn off inflammation at a genetic level,' framing this as a distinguishing feature of the clinical tools used in their practice. This claim is most directly supported by the subsequent description of KPV's NF-κB inhibition mechanism, which operates at the level of gene transcription. No specific dosages or study citations are provided for this overarching claim. It is presented as a key differentiator from standard dietary interventions.
Peptide Stack (BPC-157 + KPV + Larazotide) for Gut and Systemic Inflammation
The speaker describes a three-peptide clinical stack combining BPC-157, KPV, and Larazotide as a coordinated approach to gut and systemic inflammation. Each peptide is said to address a distinct mechanism: BPC-157 heals the gut lining and boosts antioxidants, KPV blocks NF-κB inflammatory gene activation, and Larazotide repairs tight junctions and the zonulin pathway. No individual or combined dosages are specified. This stack is presented as a standard clinical protocol in the speaker's functional medicine clinic.
KPV Peptide Blocks NF-κB — The Master Inflammatory Switch
KPV is described as entering the cell nucleus and blocking NF-κB (NF-kappa beta), which the speaker characterizes as the master inflammatory switch that controls inflammatory gene expression. By inhibiting NF-κB, KPV is said to prevent the activation of inflammatory genes at a genetic level. No specific dosage or frequency is mentioned. This is presented as a clinical tool used in the speaker's practice.
GLP-1 Medications Do Not Repair Gut Lining Despite Systemic Anti-Inflammatory Effects
Dr. Jones asserts that while GLP-1 receptor agonists reduce inflammation systemically, they do not specifically repair a compromised gut barrier. He claims that if gut barrier integrity is not restored, inflammation will continue to recycle regardless of GLP-1 medication use — establishing the rationale for adjunct peptide therapy with KPV and BPC-157.
Gut Inflammation Reduction Improves Insulin Resistance and GLP-1 Efficacy
Dr. Jones describes a compounding downstream effect: when gut inflammation is reduced (via KPV and BPC-157), insulin resistance improves, and when insulin resistance improves, the GLP-1 medication becomes more effective. He frames persistent gut inflammation as a 'bottleneck' limiting GLP-1 drug performance.
KPV Mechanism: Direct Action on Intestinal Tight Junctions
Dr. Jones describes KPV as a targeted anti-inflammatory peptide that works directly on intestinal tight junctions — the structural points where 'leaky gut' occurs. He positions it as addressing a gap that GLP-1 medications cannot fill: while GLP-1 agonists reduce systemic inflammation, they do not specifically repair the gut barrier. No dosage specified.
Oral BPC-157 + KPV Stack for Gut Inflammation
The speaker recommends combining oral BPC-157 with KPV (alpha-MSH fragment) as one of the most effective inflammation reduction protocols seen in his clinic. The combination is said to improve the gut barrier and produce downstream anti-inflammatory effects throughout the entire body. No dosages or cycling details were provided.
Integrated autoimmune protocol: root cause + peptides + medical oversight
Dr. Jones outlines a three-pillar protocol for autoimmune conditions: (1) root cause functional medicine addressing gut, inflammation, nutrients, diet, and nervous system; (2) advanced tools including low-dose naltrexone, anti-inflammatory diet, and therapeutic peptides (BPC-157, KPV, Larazotide, Thymosin Alpha-1, GLP-1s); (3) medical oversight. He emphasizes that most programs only offer one or two of these pieces, and all three are needed for success.
BPC-157, KPV, and Larazotide for gut repair and systemic inflammation in autoimmune patients
As part of a layered functional medicine protocol for autoimmune conditions, Dr. Jones recommends peptides BPC-157 ('BPC57' as spoken), KPV, and Larazotide specifically for gut repair and reducing systemic inflammation. These are positioned as advanced tools used after foundational interventions (gut health, anti-inflammatory diet, nutrient repletion) are in place. No specific dosages are provided.
KPV addresses three biological failures model (inflammation, insulin resistance, mitochondrial dysfunction)
Dr. Bachmeyer claims KPV solves his 'three biological failures' that he believes underlie every disease: (1) systemic inflammation — via melanocortin receptor activation and macrophage phenotype shifting, (2) insulin resistance — via TNF-alpha reduction improving insulin signaling (HOMA-IR decreased 35%), and (3) mitochondrial dysfunction/ATP shortage — via improved glucose uptake and removal of inflammatory mitochondrial damage. All diseases are 'the same disease with different presentations.'
KPV + TB-500 stack for comprehensive cardiovascular disease resolution
The core thesis is that KPV addresses the root cause of cardiovascular disease (chronic systemic inflammation — restoring endothelial function, resolving inflammation, stabilizing plaque) while TB-500 addresses downstream tissue damage (cardiac scarring, fibrosis, structural remodeling). Together they are positioned as a comprehensive two-pronged solution. No specific dosages or protocol timing mentioned in the available transcript.
Safety claim: cannot overdose on KPV, BPC-157, or TB-500
Dr. Bachmeyer claims that you cannot overdose and die from KPV, BPC-157, or TB-500, contrasting these with statins, NSAIDs, and prednisone which can cause fatal overdose. He argues that since the body naturally produces the parent compounds (e.g., alpha-MSH for KPV), they are inherently safer than synthetic pharmaceuticals.
KPV is immune restoration, not immunosuppression
Dr. Bachmeyer emphasizes that KPV does not suppress immune activation like NSAIDs, steroids, or corticosteroids. Instead, it restores immune regulation by repairing the immune system's natural braking mechanisms (T-regulatory cells). It is described as 'comprehensive immune optimization' rather than suppression.
KPV confers centenarian-like immune profile
Dr. Bachmeyer argues that KPV confers an immune profile similar to centenarians, who exhibit lower baseline inflammatory markers, superior inflammation resolution capacity, higher SPM levels, better endothelial function, and healthier HDL composition. The claim is that KPV enables the rapid inflammation resolution characteristic of people living past 100. Referenced context: Fuchi and Fabri in Gerontology (centenarian immune profiles).
Full EBV peptide protocol stack — TA1, KPV, SS-31, MOTS-c with supplements
The complete EBV protocol combines four peptides with nutritional support: Thymosin Alpha-1 (1 mg 2x/week, 12 weeks) for T-cell retraining, KPV (400 mcg 2x/day) for inflammatory cytokine suppression, SS-31 + MOTS-c (stacked) for mitochondrial repair. Supplements include monolaurin (titrate 500 mg to 2-3 g/day), L-lysine (2-3 g/day in 3 doses), selenium (200 mcg/day), and DGL (600 mg/day). A 2022 study (Prusty, Viruses) showed combination antiviral + immune-supportive therapy achieved 67% viral load reduction and 71% symptom improvement sustained at 12-month follow-up.
Complete HSV Peptide + Supplement Stack Protocol
Complete protocol combining immune retraining (Thymosin Alpha-1 IM 2x/week, LL-37 IM daily), direct antivirals (Monolaurin 3g/day, L-Lysine 3g/day in 3 divided doses), anti-inflammatory control (KPV 300-400mcg subQ daily), nerve repair (BPC-157 IM daily), and nutritional restoration (Magnesium glycinate 400mg, Zinc 30mg, Vitamin D3 5000IU + K2 200mcg, Selenium 200mcg, NAC 600mg 2x/day). Patient achieved zero outbreaks in 90 days after 8 years of monthly outbreaks.